Sugi Predict

Sugi Predict / Compounds / SCHEMBL460614

SCHEMBL460614

SCHEMBL460614

CCOC(=O)c1sc(-c2ccc(O)c([N+](=O)[O-])c2)nc1C

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 5/20 0.57
▸ DBF4 Q9UBU7 5/20 0.57
▸ TRPM8 Q7Z2W7 6/20 0.51
▸ MAPT P10636 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ THRA P10827 2/20 0.47
▸ THRB P10828 2/20 0.47
▸ PTPN11 Q06124 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ CRHBP P24387 1/20 0.47
▸ CRHR2 Q13324 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8867203 0.88 CDC7 (0.56) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL17309802 0.88 CDC7 (0.56) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL8868127 0.86 CDC7 (0.54) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL17309789 0.85 CDC7 (0.53) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL17629244 0.85 RAB9A (0.67) KDM4EALDH1A1RAB9ATHRATHRB
SCHEMBL17629243 0.85 RAB9A (0.67) KDM4EALDH1A1RAB9ATHRATHRB
SCHEMBL8866949 0.84 CDC7 (0.52) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL12186978 0.83 CDC7 (0.64) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL8868119 0.83 CDC7 (0.54) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL8868456 0.83 CDC7 (0.50) CDC7DBF4TRPM8MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016046836-A2 A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE EXCEL INDUSTRIES LTD. (IN) 2016-03-31 — — WO claimed
CN-119350357-A Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof 沈阳药科大学 2025-01-24 — — CN disclosed
CN-109320474-B Preparation method of febuxostat 昆明源瑞制药有限公司 2021-06-29 — — CN disclosed
WO-2016046836-A3 A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE EXCEL INDUSTRIES LTD. (IN) 2016-05-12 — — WO disclosed
WO-2016046836-A3 A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE EXCEL INDUSTRIES LTD. (IN) 2016-05-12 — — WO disclosed
WO-2016046836-A2 A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE EXCEL INDUSTRIES LTD. (IN) 2016-03-31 — — WO disclosed
WO-2016046836-A2 A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE EXCEL INDUSTRIES LTD. (IN) 2016-03-31 — — WO disclosed
WO-2016046836-A2 A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE EXCEL INDUSTRIES LTD. (IN) 2016-03-31 — — WO disclosed
US-20140228417-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS MAPI PHARMA LTD. (IL) 2014-08-14 — — US disclosed
EP-2763675-A2 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS Mapi Pharma Limited (IL) 2014-08-13 — — EP disclosed
WO-2012131590-A1 AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF SANDOZ AG (CH) 2012-10-04 — — WO disclosed
WO-2012073259-A1 NOVEL PROCESS FOR THE PREPARATION OF FEBUXOSTAT INDOCO REMEDIES LIMITED (IN) 2012-06-07 — — WO disclosed
WO-2012032528-A2 IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE NATCO PHARMA LIMITED (IN) 2012-03-15 — — WO disclosed
WO-2012032528-A2 IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE NATCO PHARMA LIMITED (IN) 2012-03-15 — — WO disclosed
WO-2011141933-A2 PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS MSN LABORATORIES LIMITED (IN) 2011-11-17 — — WO disclosed
EP-2266966-A1 A process for the preparation of febuxostat Chemo Ibérica, S.A. (ES) 2010-12-29 — — EP disclosed
WO-2010142653-A1 A PROCESS FOR THE PREPARATION OF FEBUXOSTAT CHEMO IBÉRICA, S.A. (ES) 2010-12-16 — — WO disclosed
US-5614520-A 2-arylthiazole derivatives and pharmaceutical composition thereof TEIJIN LIMITED (JP) 1997-03-25 — — US disclosed
EP-0513379-B1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LTD (JP) 1996-09-11 — — EP disclosed
EP-0513379-A1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LIMITED (JP) 1992-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228417-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS XDH, NLRP3, PNPO CDC7 4323/4885DBF4 4158/4885TRPM8 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.